Watch the whole program

Facts and Trends in Cardiovascular Deal Making

In the fourth PharmaVentures Business Review of 2007, we focus on the cardiovascular sector. In the Business Report, we take a look at the current status of the cardiovascular therapy market and investigate the trends in deal making throughout the last decade for this major segment of the pharmaceutical industry. In the Month in Review, we review the industry's key deals during March 2007 and their likely impact on the companies involved as well as the market sector. In Face-to-Face, Fintan Walton talks to Damian Marron, Vice President, Corporate Development, NicOx, about the company’s achievements to date and its ambitious plans for the future.

To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.

• Schering-Plough has agreed to acquire Organon Biosciences, the human and animal healthcare businesses of Akzo Nobel, for approximately US$14.4 B dollars in cash.
• Smith and Nephew has entered into a US$889 M agreement to purchase Plus Orthopedics, a privately held Swiss orthopaedic company.
• Eczacibasi Pharmaceuticals Manufacturing has entered into a strategic partnership with Zentiva to form a new European generics manufacturing company for a total of US$607.
• Beckman Coulter is to acquire Biosite in a cash tender offer of US$85 per share, representing a total of approximately US$1.55 B.
• Oxford BioMedica and sanofi-aventis have entered into a potential US$690 M exclusive global licensing agreement to develop and commercialise TroVax® for the treatment and prevention of cancers.

Watch this segment

The Month in Review

Learn about the key deals in March 2007 and what they have meant for the companies involved. Featured deals include those between Schering-Plough and Organon Biosciences, Beckman Coulter and Biosite, Smith & Nephew and Plus Orthopedics, and others.

To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.

• Schering-Plough has agreed to acquire Organon Biosciences, the human and animal healthcare businesses of Akzo Nobel, for approximately US$14.4 B dollars in cash.
• Smith and Nephew has entered into a US$889 M agreement to purchase Plus Orthopedics, a privately held Swiss orthopaedic company.
• Eczacibasi Pharmaceuticals Manufacturing has entered into a strategic partnership with Zentiva to form a new European generics manufacturing company for a total of US$607.
• Beckman Coulter is to acquire Biosite in a cash tender offer of US$85 per share, representing a total of approximately US$1.55 B.
• Oxford BioMedica and sanofi-aventis have entered into a potential US$690 M exclusive global licensing agreement to develop and commercialise TroVax® for the treatment and prevention of cancers.

Watch this segment

The Business Report

In the April edition of the Business Report, we focus on the cardiovascular sector, providing a review of the current market status as well as trends in deal making. We look at the key players and drivers that have enabled this market to grow over the last ten years, becoming the second largest of all therapy areas. We also investigate the trends in deal making for cardiovascular therapies, assessing both the types of deals and the stages of product development involved. Finally, we review the outlook for the cardiovascular market, highlighting some of the major deals in 2007, as well as key drug development events and how the market is forecast to grow over the next few years.

Watch this segment

Face-to-Face

Fintan Walton talks to Damian Marron, Vice President, Corporate Development, NicOx, about the company's achievements to date - from Italian origins, it developed into a rare French biopharmaceutical success story, raising some of the largest capital sums in Europe. Damian discusses NicOx's strategy with regards to attracting investors, choice of stock exchange and the rationale behind its partner selection. Also outlined are the company's objectives, ranging from its plans for the next 12 months to its long term aims regarding its conversion to a partially integrated pharmaceutical company.